Please use this identifier to cite or link to this item:
https://bura.brunel.ac.uk/handle/2438/34186| Title: | Decision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict |
| Authors: | Mohamed-Ahmed, Rayan Rantell, Angie Taithongchai, Annika Araklitis, George Robinson, Dudley |
| Keywords: | overactive bladder;patient decision aid;refractory overactive bladder;shared decision-making |
| Issue Date: | 19-May-2026 |
| Publisher: | Springer Nature |
| Citation: | Mohamed-Ahmed, R. et al. (2026) 'Decision-Making in Refractory Overactive Bladder: Evaluation of a Novel Patient Decision Aid and its Impact on Decisional Conflict', International Urogynecology Journal, 37(10), pp. 3263–3267. doi: 10.1007/s00192-026-06688-3. |
| Abstract: | Background: Refractory overactive bladder (OAB) lacks formal definition and is poorly understood. Its management requires patients to choose an invasive treatment, including intravesical botulinum toxin A (BOTOX®), sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS), which have varying rates of efficacy and side effects. These decisions can be complex for patients to make, especially within the time constraints of outpatient clinic appointments. A new patient decision aid (PDA) has been developed to support patients during this shared decision-making process. Aim: This study assesses decisional conflict scores and patient satisfaction in those who use a novel PDA for refractory OAB. Methods: Consecutive new patients with refractory OAB were provided with the PDA prior to decision-making. Patients then had a virtual follow-up appointment to assess their decisional conflict, using a validated scale. The total decisional conflict score was calculated. Treatment choice and free-text feedback were also analysed. Results: Twenty-five patients were included. Following use of the PDA, a range of treatment choices were made, including SNM (n = 6), PTNS (n = 10), BOTOX® (n = 6) and continuation with medical therapy (n = 3). Overall, decisional conflict was low, with 100% of patients having a score of less than 25. Subscores suggested improved patient understanding, with the PDA increasing clarification. Conclusion: Introduction of this novel PDA, in those requiring treatment for refractory OAB, was associated with low decisional conflict and positive patient feedback. This supports its use in shared decision-making, empowering patients to make an informed and individualised choice regarding their treatment. |
| Description: | Data Availability: The authors are happy to provide data upon reasonable request. |
| URI: | https://bura.brunel.ac.uk/handle/2438/34186 |
| DOI: | https://doi.org/10.1007/s00192-026-06688-3 |
| ISSN: | 0937-3462 |
| Appears in Collections: | Department of Health Sciences Research Papers |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| FullText.pdf | Copyright © The Author(s) 2026. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. | 555.5 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License